MyAverix Finance MyAverix Finance

BE · Other

IMMUPHARMA (25I)

Other

IMMUPHARMA (25I) is listed on BE in the Other sector. As of 2026-03-22, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-22

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 25I

P/E ratio
18.00

IMMUPHARMA (25I) — FAQ

What is 25I's P/E ratio?

The price-to-earnings (P/E) ratio for IMMUPHARMA (25I) is 18.00 (data as of 2026-03-22).

Does IMMUPHARMA pay a dividend?

Dividend yield is not available in the current snapshot for IMMUPHARMA (25I). Check the MyAverix Finance app for the latest dividend data.

What sector is IMMUPHARMA in?

IMMUPHARMA (25I) is classified in the Other sector.

What exchange is 25I listed on?

25I is listed on BE.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Other companies

Adobe Inc (ADB) AIA GROUP (7A2) Amazon.com Inc (AMZ) AMERICAN EXPRESS (AEC1) Apple Inc (APC) Berkshire Hathaway Inc (BRYN) EXXON MOBIL (XONA) Honeywell International Inc (ALD)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play